NAD+ (Nicotinamide Adenine Dinucleotide) Research Overview

Simplified Summary

NAD+ is a dinucleotide coenzyme that serves as an electron acceptor in glycolysis and the TCA cycle, cycling between oxidised (NAD+) and reduced (NADH) forms to transfer electrons to the mitochondrial electron transport chain. Beyond its role as an electron carrier, NAD+ is consumed as a substrate by three major enzyme families: sirtuins (NAD+-dependent deacylases implicated in metabolic gene regulation and ageing), PARPs (poly ADP-ribose polymerases involved in DNA repair), and CD38 (a cyclic ADP-ribose hydrolase involved in calcium signalling). Preclinical research has studied how NAD+ availability influences these enzyme activities and their downstream biological consequences.

A major focus of NAD+ preclinical research has been the relationship between declining NAD+ levels and ageing biology. Animal model studies have documented decreased tissue NAD+ concentrations with advancing age across multiple tissues, and have used supplementation and biosynthetic pathway modulation to examine whether restoring NAD+ levels influences ageing-associated phenotypes in laboratory model systems.

Key Findings Reported in Preclinical Models

• Age-associated decline in tissue NAD+ concentrations documented across multiple tissues in rodent ageing studies.
• Sirtuin (SIRT1, SIRT3) activation linked to elevated NAD+ availability in preclinical metabolic and ageing research.
• Mitochondrial function improvements in animal models with elevated NAD+ levels, including respiratory capacity and membrane potential measurements.
• PARP-mediated DNA repair activity characterised as a major consumer of NAD+ following genotoxic stress in cell-based studies.
• Muscle and neurological function outcomes in preclinical ageing and disease models with NAD+ repletion approaches.
• Circadian rhythm regulation links to NAD+ metabolism through CLOCK gene-NAMPT transcriptional feedback in preclinical model research.

Introduction

NAD+ occupies a central position in cellular metabolism as both an electron carrier and a signalling molecule. Its biosynthesis proceeds through multiple pathways including the de novo pathway from tryptophan, the Preiss-Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide. The relative contribution of each pathway to cellular NAD+ pools varies by tissue and metabolic state. Preclinical research has used isotopic labelling, genetic models, and pharmacological interventions to characterise NAD+ biosynthesis, consumption, and recycling in different biological contexts.

Research Applications

• Sirtuin biology and epigenetic regulation research using NAD+ modulation to investigate deacylase activity and downstream metabolic gene regulation.
• Mitochondrial function and ageing research examining how NAD+ levels influence electron transport chain activity and mitochondrial biogenesis.
• DNA damage response research characterising PARP-NAD+ interactions under genotoxic stress conditions.
• Metabolic disease research in animal models investigating NAD+ pathway modulation as a tool for studying metabolic dysregulation.